J&J Medical Connect
XARELTO®

(rivaroxaban)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

play/pause
Listen
(1:19 min)
audio controls

XARELTO - Transition from or to Apixaban

Last Updated: 07/23/2026

SUMMARY

  • For patients currently receiving an anticoagulant other than warfarin, start XARELTO 0 to 2 hours prior to the next scheduled evening administration of the drug (e.g., low molecular weight heparin or non-warfarin oral anticoagulant) and omit administration of the other anticoagulant. For unfractionated heparin (UFH) being administered by continuous infusion, stop the infusion and start XARELTO at the same time.1
  • For patients currently taking XARELTO and transitioning to an anticoagulant with rapid onset, discontinue XARELTO and give the first dose of the other anticoagulant (oral or parenteral) at the time that the next XARELTO dose would have been taken.1
  • No clinical data is available to guide converting patients from apixaban to XARELTO, or from XARELTO to apixaban.
  • Clinicians should use their clinical judgement to weigh benefits vs risks for each patient and refer to product labeling for each product as appropriate.2-5
  • Additional citations are included in the REFERENCES section for your review.2-9

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 06 July 2026.

References

1 XARELTO (rivaroxaban) [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf
2 Chen A, Stecker E, A Warden B. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559.  
3 Trang J, Nguyen NH, Huynh S. Guidance for transitioning among anticoagulants. AACN Adv Crit Care. 2019;30(3):209-216.  
4 Raval AN, Cigarroa JE, Chung MK, et al. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation. 2017;135(10):e604-e633.  
5 Cowell RP. Direct oral anticoagulants: integration into clinical practice. Postgrad Med J. 2014;90(1067):529-539.  
6 Strasser KM, Qasem A, Madhusudhana S. Switching between oral anticoagulants. Hosp Pract (1995). 2014;42(3):68-74.  
7 Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 41(1):206-232.  
8 Wilbur J, Shian B. Deep venous thrombosis and pulmonary embolism: current therapy. Am Fam Physician. 2017;95(5):295-302.  
9 Romagnoli A, Santoleri F, Costantini A, et al. Adherence, persistence and switching rates of apixaban, dabigatran and rivaroxaban in non-valvular atrial fibrillation: a multicentre real-life analysis at 3 years. Eur J Hosp Pharm. 2024;31(2):156-161.  

Would you like to clear and leave your conversation? Message history will be lost.